AbbVie Completes Acquisition of Capstan Therapeutics
AbbVie (NYSE:ABBV) has completed its acquisition of Capstan Therapeutics, gaining access to a pioneering targeted lipid nanoparticle (tLNP) platform and its lead asset CPTX2309.
The acquisition brings a Phase 1 candidate for B cell-mediated autoimmune diseases that generates CD19-specific, CD8+ in vivo CAR-T cells. This innovative therapy aims to achieve durable, drug-free remission through rapid B cell depletion, without requiring lymphodepleting chemotherapy and avoiding traditional CAR-T therapy challenges.
The integration strengthens AbbVie's capability to develop treatments focused on immune system reset and expands the application of Capstan's proprietary technology for in vivo cell programming.
AbbVie (NYSE:ABBV) ha completato l'acquisizione di Capstan Therapeutics, ottenendo l'accesso a una piattaforma pionieristica di nanoparticelle lipidiche mirate (tLNP) e all'asset principale CPTX2309.
L'operazione include un candidato in Fase 1 per patologie autoimmuni mediate dalle cellule B, in grado di generare in vivo cellule CAR-T CD8+ specifiche per CD19. Questa terapia innovativa punta a una remissione duratura senza farmaci mediante una rapida deplezione delle cellule B, senza necessit脿 di chemioterapia linfodepletiva e superando le criticit脿 delle CAR-T tradizionali.
L'integrazione rafforza la capacit脿 di AbbVie nello sviluppo di terapie mirate al reset del sistema immunitario e ne amplia le applicazioni della tecnologia proprietaria di Capstan per la programmazione cellulare in vivo.
AbbVie (NYSE:ABBV) ha completado la adquisici贸n de Capstan Therapeutics, obteniendo acceso a una plataforma pionera de nanopart铆culas lip铆dicas dirigidas (tLNP) y a su activo principal CPTX2309.
La compra incorpora un candidato de Fase 1 para enfermedades autoinmunes mediadas por c茅lulas B, que genera in vivo c茅lulas CAR-T CD8+ espec铆ficas para CD19. Esta terapia innovadora busca lograr una remisi贸n duradera sin f谩rmacos mediante una r谩pida depleci贸n de c茅lulas B, sin requerir quimioterapia linfodeplectora y evitando los retos de las CAR-T tradicionales.
La integraci贸n fortalece la capacidad de AbbVie para desarrollar tratamientos centrados en el reinicio del sistema inmunitario y ampl铆a la aplicaci贸n de la tecnolog铆a propia de Capstan para la programaci贸n celular in vivo.
AbbVie (NYSE:ABBV)臧赌 Capstan Therapeutics 鞚胳垬毳� 鞕勲頃橃棳 靹犽弰鞝侅澑 響滌爜 歆�歆� 雮橂吀鞛呾瀽(tLNP) 頂岆灚韽缄臣 欤检殧 韺岇澊頂勲澕鞚胳澑 CPTX2309鞐� 鞝戧芳 甓岉暅鞚� 頇曤炒頄堨姷雼堧嫟.
鞚措矆 鞚胳垬鞐愲姅 CD19 韸轨澊鞝� CD8+ in vivo CAR-T 靹疙彫毳� 靸濎劚頃橂姅 鞛勳儊 1靸� 頉勲炒氍检鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞚� 順侅嫚鞝� 旃橂氩曥潃 毽柬攧甑� 鞝滉卑 頇旐暀鞖旊矔 鞐嗢澊 牍犽ジ B 靹疙彫 鞝滉卑毳� 韱淀暣 鞎诫 牍勳潣臁挫爜鞚搓碃 歆�靻嶌爜鞚� 甏�頃措ゼ 雼劚頃橂姅 瓴冹潉 氇╉憸搿� 頃橂┌, 旮办〈 CAR-T 旃橂鞚� 頃滉硠毳� 須岉敿頃╇媹雼�.
韱淀暕鞚� 韱淀暣 AbbVie鞚� 氅挫棴瓿� 毽厠 欷戩嫭 旃橂 臧滊皽 鞐焿鞚� 臧曧檾霅橁碃, Capstan鞚� 瓿犾湢頃� in vivo 靹疙彫 頂勲攴鸽灅氚� 旮办垹 鞝侅毄 氩旍渼臧赌 頇曤寑霅╇媹雼�.
AbbVie (NYSE:ABBV) a finalis茅 l'acquisition de Capstan Therapeutics, obtenant l'acc猫s 脿 une plateforme pionni猫re de nanoparticules lipidiques cibl茅es (tLNP) et 脿 son principal asset CPTX2309.
Cette acquisition inclut un candidat de phase 1 pour les maladies auto-immunes m茅di茅es par les cellules B, capable de g茅n茅rer in vivo des cellules CAR鈥慣 CD8+ sp茅cifiques de CD19. Cette th茅rapie innovante vise une r茅mission durable sans m茅dicaments gr芒ce 脿 une d茅pl茅tion rapide des cellules B, sans n茅cessiter de chimioth茅rapie lymphod茅pl茅tante et en 茅vitant les limites des th茅rapies CAR鈥慣 classiques.
Cette int茅gration renforce la capacit茅 d'AbbVie 脿 d茅velopper des traitements visant le r茅initialisation du syst猫me immunitaire et 茅tend l'application de la technologie propri茅taire de Capstan pour la programmation cellulaire in vivo.
AbbVie (NYSE:ABBV) hat die 脺bernahme von Capstan Therapeutics abgeschlossen und damit Zugriff auf eine wegweisende Plattform f眉r zielgerichtete Lipid-Nanopartikel (tLNP) sowie auf das Leittopic CPTX2309 erhalten.
Die 脺bernahme bringt einen 笔丑补蝉别鈥�1-碍补苍诲颈诲补迟别苍 f眉r B鈥慫ell-vermittelte Autoimmunerkrankungen, der in vivo CD19鈥憇pezifische CD8+-CAR鈥慣鈥慫ellen erzeugt. Diese neuartige Therapie zielt auf eine dauerhafte, medikamentenfreie Remission durch schnelle B鈥慫ell鈥慐limination ab, ohne lymphodepletive Chemotherapie und ohne die typischen Herausforderungen herk枚mmlicher CAR鈥慣鈥慣herapien.
Die Integration st盲rkt AbbVies F盲higkeit, Therapien zum Reset des Immunsystems zu entwickeln, und erweitert die Anwendbarkeit von Capstans propriet盲rer Technologie zur in vivo Zellprogrammierung.
- Acquisition of innovative tLNP platform technology for in vivo cell programming
- Phase 1 candidate CPTX2309 offers potential first-in-class treatment for autoimmune diseases
- Technology eliminates need for lymphodepleting chemotherapy
- Platform enables broader applications for in vivo programming of cells
- CPTX2309 still in early Phase 1 development with unproven efficacy
- Integration risks associated with technology platform acquisition
- Acquisition adds a potential first-in-class in听vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo
Capstan's lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The CAR-T cells are designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies.
"With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The addition of CPTX2309 and Capstan's tLNP platform strengthens our ability to deliver new treatments aimed at resetting the immune system and enables application of Capstan's proprietary technology more broadly for in vivo programming of cells."
For additional background on the acquisition, please read the press release announcing the definitive agreement under which AbbVie will acquire Capstan .
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas 鈥� immunology, oncology, neuroscience, and eye care 鈥� and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on 听, , , and .
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Media: Lindsay Cangemi | Investors: Liz Shea |
听
听
View original content to download multimedia:
SOURCE AbbVie
FAQ
What did AbbVie acquire with the Capstan Therapeutics purchase?
What is special about Capstan's CPTX2309 therapy?
How will the Capstan acquisition benefit AbbVie's pipeline?
What stage of development is CPTX2309 in?
What advantages does CPTX2309 offer over traditional CAR-T therapies?
